Codexis (CDXS) Set to Announce Earnings on Thursday

Codexis (NASDAQ:CDXS) is scheduled to release its earnings data after the market closes on Thursday, May 2nd. Analysts expect Codexis to post earnings of ($0.17) per share for the quarter. Codexis has set its FY 2024 guidance at EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

Codexis (NASDAQ:CDXS) last posted its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.18. Codexis had a negative return on equity of 47.58% and a negative net margin of 108.69%. The company had revenue of $26.56 million during the quarter, compared to analysts’ expectations of $24.73 million. On average, analysts expect Codexis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Codexis Trading Down 4.6 %

Shares of CDXS stock opened at $2.91 on Wednesday. Codexis has a twelve month low of $1.45 and a twelve month high of $4.91. The stock has a market capitalization of $205.33 million, a price-to-earnings ratio of -2.62 and a beta of 2.01. The stock has a fifty day simple moving average of $3.30 and a two-hundred day simple moving average of $2.74.

Analysts Set New Price Targets

CDXS has been the subject of several research reports. StockNews.com upgraded Codexis to a “sell” rating in a report on Tuesday, March 5th. Benchmark upgraded Codexis from a “hold” rating to a “buy” rating and set a $9.00 target price for the company in a report on Thursday, February 29th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $6.80.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.